Have we made progress with biological agents in metastatic colorectal cancer? Eric Van Cutsem Editorial 23 March 2007 Pages: 59 - 62
Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study G. RobinetF. BarlesiC. Chouaid Original Research 27 February 2007 Pages: 63 - 71
Targeted therapies in head and neck cancer Pol M. SpecenierJan B. Vermorken Review 21 March 2007 Pages: 73 - 88
Targeted therapy for small cell lung cancer Apar Kishor GantiAmit W. Panwalkar Review 28 February 2007 Pages: 89 - 97
Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma Alain RavaudHenri de ClermontJean Philippe Maire Review 27 February 2007 Pages: 99 - 105
Lapatinib: a novel dual tyrosine kinase inhibitor Simon ChowdhuryLisa M. PickeringPaul A. Ellis Review 10 March 2007 Pages: 107 - 112
The value of innovation: the economics of targeted drugs for cancer Cara C. TigueKaren A. FitznerCharles L. Bennett Perspectives 21 March 2007 Pages: 113 - 119
Highlights from the pharmacology and molecular mechanisms group annual meeting Perspectives 07 March 2007 Pages: 121 - 132